Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
Company profile
Website
CEO
Richard F. Pops
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
232472830
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
19 May 20
CT ORDER
Confidential treatment order
18 Mar 19
CT ORDER
Confidential treatment order
19 Feb 16
CT ORDER
Confidential treatment order
11 Jan 16
15-12B
Securities registration termination
16 Sep 11
25-NSE
Exchange delisting
16 Sep 11
8-K
Submission of Matters to a Vote of Security Holders
8 Sep 11
DEFM14A
Proxy related to merger
5 Aug 11
DEFA14A
Additional proxy soliciting materials
2 Aug 11
10-Q
2011 Q2
Quarterly report
1 Aug 11
Latest ownership filings
Institutional ownership, Q3 2023
98.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 297 |
Opened positions | 51 |
Closed positions | 35 |
Increased positions | 138 |
Reduced positions | 76 |
13F shares | Current |
---|---|
Total value | 4.50 tn |
Total shares | 161.39 mm |
Total puts | 269.80 k |
Total calls | 768.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.67 mm | $522.87 bn |
BLK Blackrock | 17.16 mm | $480.69 bn |
Wellington Management | 11.75 mm | $329.03 bn |
Sarissa Capital Management | 7.04 mm | $197.25 bn |
Renaissance Technologies | 6.12 mm | $171.89 bn |
STT State Street | 6.09 mm | $170.62 bn |
Hardman Johnston Global Advisors | 5.61 mm | $157.08 bn |
Pictet Asset Management Holding | 5.48 mm | $153.61 bn |
Primecap Management | 3.88 mm | $108.74 bn |
Deep Track Capital | 3.80 mm | $106.44 bn |